GET DAILY SIGNALSWhy Is ImmunityBio (IBRX) Stock Down -22.11% Today?
Key Takeaways
- Shares plunged 22.11% to roughly $6.73 in early trading on November 9, 2026, from a prior close of $8.64.
- Primary catalyst: A third-quarter 2026 earnings miss on both revenue and adjusted EPS, paired with a going-concern warning from management.
- Secondary drivers: A sharply widened net loss, elevated liabilities, and disclosed insider share sales added to the selling pressure.
- Broader market context: The decline was company-specific, with the S&P 500, Dow Jones, and Nasdaq all trading higher.
- What traders are watching next: The company's funding and cash runway, upcoming clinical data, and any analyst estimate revisions.
- For deeper insight into this stock, explore its Price Targets, Earnings, and Forecast pages.
- Discover how AI-driven strategies are positioned in this market on the Trending AI Robots page.
Opening Summary
IBRX, the Nasdaq-listed ticker of ImmunityBio, Inc., a commercial-stage immunotherapy company best known for its ANKTIVA bladder-cancer franchise, tumbled sharply on Monday, November 9, 2026. The stock fell 22.11% to around $6.73, down from a previous-session close of $8.64, after the company reported third-quarter results that missed Wall Street expectations on both the top and bottom lines. The move was driven almost entirely by company-specific factors, as the broader equity market advanced during the same session.
Earnings Miss and Going-Concern Warning
The dominant catalyst behind the selloff was a disappointing third-quarter 2026 report released before the open. IBRX posted adjusted earnings per share of approximately -$0.09, wider than the consensus estimate of -$0.07, while revenue of $48.84 million came in more than $10 million short of the roughly $59.23 million analysts had expected. The company's net loss swelled to $184.6 million for the quarter, a dramatic expansion from $67.3 million in the year-ago period, driven partly by non-cash fair-value adjustments and higher interest expense.
Balance-Sheet and Insider-Selling Concerns
Compounding the earnings disappointment, management included a going-concern disclosure citing substantial doubt about the company's ability to continue operations without additional financing or support from related parties, against a backdrop of roughly $1.75 billion in total liabilities. Reports that two board members sold shares under prearranged Rule 10b5-1 trading plans further unsettled investors, even though insiders still hold the majority of the company's stock. Together, these financial warning signs outweighed the session's positive clinical news.
Clinical Progress Was Overshadowed
Notably, the earnings release coincided with genuinely positive pipeline updates. ImmunityBio said its QUILT-2.005 trial of ANKTIVA plus BCG met its primary efficacy endpoint in BCG-naive, non-muscle-invasive bladder cancer patients, and that Israel had granted approval for ANKTIVA. In a normal environment, these milestones might have supported the stock. Instead, the market reaction was dominated by the revenue shortfall, the widening loss, and the going-concern language, sending shares sharply lower despite the encouraging data.
Market Context and Trading Activity
The decline in IBRX stood in stark contrast to a broadly constructive tape. The S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all advanced on the day, underscoring that the move was a single-name event rather than a reflection of macro or sector headwinds. Trading activity was heavy as investors re-rated the stock, which had surged more than 300% over the prior 52 weeks and carried an analyst consensus of "Moderate Buy" with an average price target near $16 heading into the report. The sharp gap lower broke the stock well below key short- and medium-term moving averages, reflecting deteriorating technical momentum.
What Comes Next for IBRX
Investors will now focus on ImmunityBio's path to securing additional capital, the sustainability of its commercial ramp for ANKTIVA, and further readouts from the QUILT-2.005 program. The company has indicated it remains on track to submit a supplemental Biologics License Application in the fourth quarter of 2026. The degree to which analysts revise revenue and earnings estimates in the days following the report, along with any clarification from management on its financing plans, will be critical for the stock's near-term direction. Risks include continued cash burn, dilution from potential capital raises, and execution risk around the commercial launch.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots that are currently performing strongly under prevailing market conditions. While Tickeron offers hundreds of bots covering thousands of tickers, only the top performers are featured in this section, with each bot differing by strategy, timeframe, performance metrics, and traded symbols. Explore the page to see how AI strategies are navigating today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
IBRX sees MACD Histogram crosses below signal line
IBRX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 16, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 53 instances where the indicator turned negative. In 50 of the 53 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for IBRX moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 similar instances where the indicator moved out of overbought territory. In 17 of the 20 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
IBRX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IBRX crossed bearishly below the 50-day moving average on October 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for IBRX entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 61 of 68 cases where IBRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on IBRX as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
Following a +12.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRX advanced for three days, in 212 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
IBRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 9 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-8.744) is normal, around the industry mean (3.498). P/E Ratio (-9.089) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (47.847) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. IBRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 66 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IBRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a producer of cancer treatment products
Industry Biotechnology
Advertisement